Oxford Nanopore Technologies develops and commercializes nanopore-based DNA and RNA sequencing technology enabling real-time, long-read genomic analysis at any scale. The company manufactures sequencing instruments (MinION, GridION, PromethION) and flow cells for applications spanning research, diagnostics, and environmental monitoring.
Oxford Nanopore Technologies is publicly traded
IPO'd on September 30, 2021
This company is no longer available on our private secondary market. Shares can be traded publicly under ONT.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2005
Employees
1,200–1,400
Total Funding
$1.09B
15 rounds
Last Private Valuation
$3.4B
May 4, 2021
Total raised $1.09B across 15 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series H+ (pre-IPO)
Date
May 4, 2021
Amount
$270.7M
Valuation
$3.4B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| May 4, 2021 | Series H+ (pre-IPO) | $270.7M | $3.4B | Not disclosed |
| October 13, 2020 | Series H+ | $109.2M | — | Not disclosed |
| January 2, 2020 | Series H | $38.6M | — | Not disclosed |
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Valuation indexed to 1.0× at the selected entry round. Valuation marks are estimates and may contain errors. Hover each dot to compare.
Entry · Late-stage venture
$2.1B
Mar 2018
Oxford Nanopore Technologies today
$3.4B
May 2021 · latest mark
Oxford Nanopore Technologies multiple
1.6x
valuation uplift since first round
Y-axis is logarithmic. Hollow dots = estimated valuations. Does not represent realized investor returns.
Francis Van Parys
Chief Executive Officer
Gordon Sanghera
Co-founder
Spike Willcocks
Chief Strategy Officer
Clive Brown
Chief Technology Officer
Nick Keher
Chief Financial Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Illumina
Global leader in next-generation sequencing with short-read platforms and comprehensive genomics solutions.
Pacific Biosciences
Developer of long-read sequencing systems and SMRT technology for genomic research.
10X Genomics
Provides solutions for single-cell and spatial genomics analysis applications.
Thermo Fisher Scientific
Diversified life sciences company offering next-generation sequencing platforms and reagents.
Yes, Oxford Nanopore Technologies is publicly traded under the ticker symbol ONT on the LSE. The company went public in September 30, 2021.
Oxford Nanopore Technologies trades under the ticker symbol ONT on the LSE. It began trading in September 30, 2021.
Oxford Nanopore Technologies (ONT on the LSE) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker ONT to place an order.
Oxford Nanopore Technologies went public in September 30, 2021 via ipo, with an offering valuation of approximately $3.4B. Oxford Nanopore Technologies completed its initial public offering on the London Stock Exchange on 30 September 2021 under ticker ONT. The IPO raised £350 million in primary shares, valuing the company at approximately £3.4 billion ($4.6 billion USD). The company priced shares at 425 pence and experienced strong first-day trading, with stock climbing 45% within the first hour. Oracle Corporation participated as a strategic cornerstone investor with a £150 million investment.
Oxford Nanopore Technologies raised $1.09B across 15 disclosed funding rounds prior to its public listing.
Oxford Nanopore Technologies was founded by Gordon Sanghera in 2005.
Oxford Nanopore Technologies is headquartered in Oxford, United Kingdom.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.